CaHA vs PLLA vs PCL: Choosing a Collagen Biostimulator

What Separates a Filler from a Biostimulator?

The commercial line between a volumising implant and a regenerative input is not a legal one. It is a description of what the injected material is designed to do and how it is presented to the account.

A conventional HA filler is a pre-formed hydrogel. It arrives as a finished, sterile, cross-linked gel in a syringe, and its job is to occupy tissue volume. A collagen biostimulator arrives as a solid or suspended active material — microspheres, a lyophilised powder, a particulate system — and is intended to sit in the tissue supporting a host response, with the injected material itself gradually clearing.

That distinction drives everything downstream: how the product is ordered, stored, released from a cold chain, reconstituted if necessary, and specified on a purchase order. This article compares the three material families a distributor is most likely to be asked to quote: CaHA, PLLA, and PCL.

---

Material Chemistry: Three Different Building Blocks

Calcium Hydroxylapatite (CaHA)

CaHA is a mineral. The active microspheres are calcium hydroxylapatite — the same calcium phosphate mineral family as the mineral phase of bone and tooth enamel — suspended in an aqueous gel carrier. Because the carrier is a gel that can be formulated to a defined viscosity rather than a rigid solid, a CaHA presentation has two coexisting characteristics: immediate space-occupying support from the gel, and a particulate phase that remains present as a scaffold while the carrier dissipates.

Poly-L-Lactic Acid (PLLA)

PLLA is a synthetic, biodegradable polymer from the poly-alpha-hydroxy acid family. It is supplied as a lyophilised (freeze-dried) powder in a sterile vial, not as a gel. The material itself has no viscosity and provides no immediate volume; the entire presentation is dry. Any gel state is created in the clinic by the operator at the point of reconstitution.

Polycaprolactone (PCL)

PCL is also a synthetic, biodegradable polymer, but a distinct one. Where PLLA is drawn from the alpha-hydroxy acid family, polycaprolactone is a polyester with a longer aliphatic chain, which changes its thermal behaviour and its handling profile. Critically, PCL is frequently supplied in a ready-to-inject, non-lyophilised form: a pre-made suspension of PCL microspheres in a gel carrier. That is the structural difference that matters most at the procurement level, because it removes both the reconstitution step and the associated shelf-life clock.

Property	CaHA	PLLA	PCL
Material class	Mineral (calcium phosphate)	Synthetic biodegradable polymer	Synthetic biodegradable polyester
Physical form as shipped	Microsphere suspension in gel	Lyophilised dry powder	Microsphere suspension in gel
Reconstitution required	No	Yes — solvent added at clinic	No (ready-to-inject formats)
Carrier phase	Aqueous gel, pre-formulated	Created by operator	Gel carrier, pre-formulated
Immediate structural support	Yes — gel carrier contributes at injection	No — material alone is not viscous	Yes — gel carrier contributes at injection

---

Shelf Life, Storage, and Cold-Chain Reality

Storage is where a specification sheet quietly decides the warehouse layout.

A lyophilised PLLA vial is a dry, sealed system. Its stability profile is governed by the dry state, and it can generally be held at controlled room temperature as a stock-keeping line rather than a refrigerated one — subject to the manufacturer’s stated label conditions. A CaHA or PCL suspension is a liquid-filled, aqueous system, and aqueous systems in healthcare logistics carry different storage and transport assumptions: temperature excursions during freight touch the product’s physical state directly.

For a distributor running one warehouse, the practical consequence is that PLLA stock and CaHA/PCL stock do not belong in the same operational bucket.

Storage Dimension	CaHA	PLLA	PCL
State at rest	Liquid suspension	Dry powder	Liquid suspension
Typical label storage	Controlled temperature, protect from freezing	Controlled room temperature (label-defined)	Controlled temperature, protect from freezing
Freeze risk on a shipment	Relevant — freezing can alter a suspension	Not applicable to dry powder	Relevant
Temperature excursion sensitivity	High — aqueous dispersed phase	Lower — dry solid	High
Expiry counted from	Manufacture / sterilisation	Manufacture / lyophilisation	Manufacture

A distributor that orders all three families against one logistics plan will mis-cost at least one of them. Dry PLLA favours a longer, flatter holding pattern; a suspension favours faster turnover and stricter freight discipline.

---

The Reconstitution Protocol Belongs in the Quotation

For PLLA, the number a procurement lead needs is not the vial price. It is the cost and time of the full reconstitution workflow, because none of it happens at the factory.

Reconstitution introduces a set of variables that have no equivalent in a ready-to-use presentation:

1. The diluent. The solvent is ordered separately from the active vial and becomes its own SKU, its own storage line, and its own line on the invoice.
2. The hydration interval. After wetting, the powder needs time to hydrate. The interval is a clinical timeline, not a warehouse one, and it determines how early a session must be prepared relative to its booked start time.
3. The mixing step. Mechanical agitation is performed by the operating clinic, not by the manufacturer, so homogeneity depends on operator technique and equipment.
4. Right-first-time failure. A vial wetted wrong is not recoverable inventory. Reconstitution converts a stock item into a consumable with a short usability window.

By contrast, a CaHA or PCL pre-filled syringe arrives as a sterile, single-use, finished presentation. The clinic opens it and injects. Nothing is prepared on site, nothing is mixed, and the manufacturer carries the homogeneity risk.

Practical rule for a quotation: price the PLLA line as active vial + diluent + operator time + short usability window. Price the CaHA and PCL lines as syringe + freight. Comparing headline vial price against headline syringe price understates the delivered cost of the PLLA plan.

---

Unit Languages and Specification Verification at Intake

The three families declare their active content in three different units. Getting this wrong on a purchase order is the most common specification error we see in incoming enquiries.

Percent (% w/v): the CaHA convention

A CaHA presentation is typically described by the concentration of microspheres in the suspension, commonly expressed as 30% w/v in a 1 mL format. Percent tells a buyer how densely the particulate phase is loaded into the carrier — it is a concentration, not a dose.

Milligrams (mg): the PLLA convention

A PLLA presentation is typically described by dry active mass per vial, commonly shown as 365 mg. Milligrams tell a buyer how much solid material is in the vial before any diluent is added — it is a mass, not a concentration, and it says nothing about the final suspension density until the reconstitution volume is defined.

Milligrams plus volume: the PCL convention

A ready-to-inject PCL presentation is described by both a mass and a volume, so the two figures together define the suspension density directly — the same way an HA filler’s mg/mL defines its own.

The units are not interchangeable and cannot be normalised into one another. A buyer who tries to rank 30% CaHA against 365 mg PLLA against an X mg/Y mL PCL has produced a comparison with no physical meaning.

Specification Item	CaHA	PLLA	PCL
Active-content unit	% w/v (microspheres in suspension)	mg (dry powder per vial)	mg + mL (suspension density)
Format on the box	Suspension concentration	Vial mass	Mass per volume
Does it define dosing?	No — a concentration	No — a mass	Partly — density is defined, dose is not
What to verify on the COA	Microsphere content, sterility, particle sizing	Identity, residual moisture, sterility, endotoxin	Microsphere content, gel carrier, sterility, endotoxin
Common buyer error	Reading % as a dose	Reading mg as a finished concentration	Reading mg alone without the paired volume

The specification audit at goods-in

Whatever the family, four items should be confirmed against the batch documentation before stock is accepted into saleable inventory:

• Exact presentation figure — the declared percent, milligram mass, or mass-per-volume, matched to the approved product specification rather than to the marketing sheet.
• Batch-specific certificate of analysis — not a generic specification sheet.
• Sterility and endotoxin statement — batch-linked, not a standing declaration.
• Label storage condition and expiry — read off the physical carton, not the catalogue PDF.

For PLLA, add the supplied diluent to the audit checklist. A vial without its matched solvent is not a complete saleable unit.

---

Market Context: Why the CaHA Category Is Drawing Capital

The broader dermal filler market has been tracked by Persistence Market Research in its recurring dermal fillers coverage, and Grand View Research has published a dedicated calcium hydroxylapatite fillers market report. Two structural observations are worth carrying into a category decision, without treating any single growth forecast as a certainty:

• CaHA occupies a two-in-one position. A CaHA presentation is specified as a suspension that contributes structural support at injection and remains present as a mineral particulate phase. That dual description makes it attractive to accounts that want structural volumisation without committing to a two-product protocol.
• PLLA has expanded beyond the face. The FDA approval of Galderma’s Sculptra for a body indication in March 2025 moved a well-known PLLA product into a new anatomical territory, which changes how buyers think about vial-count planning for body protocols versus facial ones. Body protocols are frequently multi-vial, which changes case economics in a way that facial protocols do not.

Neither observation is a clinical claim. Both are procurement-relevant, because they change the unit economics and the reorder pattern of the category.

---

How to Specify a Biostimulator Line on a Purchase Order

Specify CaHA when: the account wants a pre-formulated suspension that can be ordered as a finished, sterile, single-use presentation, with the active content declared as a microsphere percentage. Expect to verify the percent figure, particle sizing, and the batch’s sterility statement. A CaHA line suits accounts that want one SKU to carry both a loading description and an ongoing maintenance description.

Specify PLLA when: the account is structured for a multi-session protocol and can absorb the reconstitution workflow — diluent stock, hydration interval, and operator mixing. Expect the active content to be declared in milligrams of dry powder, and expect to add the matched solvent as a second line item. This line rewards accounts that plan sessions in advance.

Specify PCL when: the account wants a synthetic polymer presentation that arrives ready to inject and is handled at controlled temperature without a reconstitution step. Expect the active content to be declared as a mass per volume, and expect the same aqueous-suspension logistics discipline you already apply to a gel-filled syringe.

In all three cases, the intake audit is the same discipline: match the declared presentation figure to the approved specification, demand a batch-level certificate, and read the storage condition off the carton. The chemistry differs; the verification does not.